JP2009530287A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009530287A5 JP2009530287A5 JP2009500457A JP2009500457A JP2009530287A5 JP 2009530287 A5 JP2009530287 A5 JP 2009530287A5 JP 2009500457 A JP2009500457 A JP 2009500457A JP 2009500457 A JP2009500457 A JP 2009500457A JP 2009530287 A5 JP2009530287 A5 JP 2009530287A5
- Authority
- JP
- Japan
- Prior art keywords
- urea
- adamanto
- piperidin
- adamantan
- ureido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1-acetyl-piperidin-4-yl Chemical group 0.000 claims 30
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 30
- 239000004202 carbamide Substances 0.000 claims 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 239000005711 Benzoic acid Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims 3
- 108020002908 Epoxide hydrolase Proteins 0.000 claims 3
- 102100025357 Lipid-phosphate phosphatase Human genes 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 229940121865 Endothelin receptor agonist Drugs 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 239000002309 endothelin receptor agonist Substances 0.000 claims 2
- 125000004474 heteroalkylene group Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- UKNFMYOQCRGBRG-UHFFFAOYSA-N 1,3-bis(1-benzoylpiperidin-4-yl)urea Chemical compound C1CN(C(=O)C=2C=CC=CC=2)CCC1NC(=O)NC(CC1)CCN1C(=O)C1=CC=CC=C1 UKNFMYOQCRGBRG-UHFFFAOYSA-N 0.000 claims 1
- AEGYWLZLEJYWCI-UHFFFAOYSA-N 1,3-di(piperidin-4-yl)urea Chemical compound C1CNCCC1NC(=O)NC1CCNCC1 AEGYWLZLEJYWCI-UHFFFAOYSA-N 0.000 claims 1
- LTDFSPICBQXVRT-UHFFFAOYSA-N 1-(1-acetylpiperidin-4-yl)-3-cycloheptylurea Chemical compound C1CN(C(=O)C)CCC1NC(=O)NC1CCCCCC1 LTDFSPICBQXVRT-UHFFFAOYSA-N 0.000 claims 1
- HAMLMZMEEHRTDE-UHFFFAOYSA-N 1-[1-(2,2,2-trifluoroacetyl)piperidin-4-yl]-3-[4-(trifluoromethoxy)phenyl]urea Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)NC1CCN(C(=O)C(F)(F)F)CC1 HAMLMZMEEHRTDE-UHFFFAOYSA-N 0.000 claims 1
- SDLXTGGQDFKXAN-UHFFFAOYSA-N 1-[1-[5-(dimethylamino)naphthalen-1-yl]sulfonylpiperidin-4-yl]-3-[4-(trifluoromethoxy)phenyl]urea Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)N(CC1)CCC1NC(=O)NC1=CC=C(OC(F)(F)F)C=C1 SDLXTGGQDFKXAN-UHFFFAOYSA-N 0.000 claims 1
- OQUBJMPZLVFOHL-UHFFFAOYSA-N 1-piperidin-4-yl-3-[4-(trifluoromethoxy)phenyl]urea Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)NC1CCNCC1 OQUBJMPZLVFOHL-UHFFFAOYSA-N 0.000 claims 1
- CLOXGPRROIYAAA-UHFFFAOYSA-N 3-[4-(1-adamantylcarbamoylamino)piperidine-1-carbonyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)N2CCC(CC2)NC(=O)NC23CC4CC(CC(C4)C2)C3)=C1 CLOXGPRROIYAAA-UHFFFAOYSA-N 0.000 claims 1
- IRTMVJNCMPHILQ-UHFFFAOYSA-N 4-[4-(1-adamantylcarbamoylamino)piperidin-1-yl]-4-oxobutanoic acid Chemical compound C1CN(C(=O)CCC(=O)O)CCC1NC(=O)NC1(C2)CC(C3)CC2CC3C1 IRTMVJNCMPHILQ-UHFFFAOYSA-N 0.000 claims 1
- FFPLXOLVISJYSA-UHFFFAOYSA-N 4-[4-(1-adamantylcarbamoylamino)piperidine-1-carbonyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(=O)N1CCC(NC(=O)NC23CC4CC(CC(C4)C2)C3)CC1 FFPLXOLVISJYSA-UHFFFAOYSA-N 0.000 claims 1
- LQEIDTKXJQSMDP-UHFFFAOYSA-N 5-[4-(1-adamantylcarbamoylamino)piperidin-1-yl]-5-oxopentanoic acid Chemical compound C1CN(C(=O)CCCC(=O)O)CCC1NC(=O)NC1(C2)CC(C3)CC2CC3C1 LQEIDTKXJQSMDP-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940121819 ATPase inhibitor Drugs 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- UAKAZEQUWPXSOS-UHFFFAOYSA-N N-(1-acetylpiperidin-4-yl)-N'-[4-(trifluoromethoxy)phenyl]urea Chemical compound C1CN(C(=O)C)CCC1NC(=O)NC1=CC=C(OC(F)(F)F)C=C1 UAKAZEQUWPXSOS-UHFFFAOYSA-N 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 229940122344 Peptidase inhibitor Drugs 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000035868 Vascular inflammations Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- OCFOPNVRCYYBBM-UHFFFAOYSA-N methyl 2-[4-(1-adamantylcarbamoylamino)piperidine-1-carbonyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1C(=O)N1CCC(NC(=O)NC23CC4CC(CC(C4)C2)C3)CC1 OCFOPNVRCYYBBM-UHFFFAOYSA-N 0.000 claims 1
- RGNDRWVROQMEET-UHFFFAOYSA-N methyl 3-[4-(1-adamantylcarbamoylamino)piperidine-1-carbonyl]benzoate Chemical compound COC(=O)C1=CC=CC(C(=O)N2CCC(CC2)NC(=O)NC23CC4CC(CC(C4)C2)C3)=C1 RGNDRWVROQMEET-UHFFFAOYSA-N 0.000 claims 1
- QHDSXIUQMDHLCI-UHFFFAOYSA-N methyl 4-[4-(1-adamantylcarbamoylamino)piperidin-1-yl]-4-oxobutanoate Chemical compound C1CN(C(=O)CCC(=O)OC)CCC1NC(=O)NC1(C2)CC(C3)CC2CC3C1 QHDSXIUQMDHLCI-UHFFFAOYSA-N 0.000 claims 1
- ZCIPBCBYSLHGOA-UHFFFAOYSA-N methyl 4-[4-(1-adamantylcarbamoylamino)piperidine-1-carbonyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(=O)N1CCC(NC(=O)NC23CC4CC(CC(C4)C2)C3)CC1 ZCIPBCBYSLHGOA-UHFFFAOYSA-N 0.000 claims 1
- AWXWKJFTKSEYNE-UHFFFAOYSA-N methyl 5-[4-(1-adamantylcarbamoylamino)piperidin-1-yl]-5-oxopentanoate Chemical compound C1CN(C(=O)CCCC(=O)OC)CCC1NC(=O)NC1(C2)CC(C3)CC2CC3C1 AWXWKJFTKSEYNE-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78217206P | 2006-03-13 | 2006-03-13 | |
| US60/782,172 | 2006-03-13 | ||
| PCT/US2007/006412 WO2007106525A1 (en) | 2006-03-13 | 2007-03-13 | Piperidinyl, indolyl, pirinidyl, morpholinyl and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammations and other diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009530287A JP2009530287A (ja) | 2009-08-27 |
| JP2009530287A5 true JP2009530287A5 (enExample) | 2010-05-06 |
| JP5298005B2 JP5298005B2 (ja) | 2013-09-25 |
Family
ID=38229180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500457A Expired - Fee Related JP5298005B2 (ja) | 2006-03-13 | 2007-03-13 | 高血圧、炎症および他の疾患の治療のための可溶性エポキシドヒドロラーゼの阻害剤としてのピペリジニル、インドリル、ピリニジル、モルホリニルおよびベンズイミダゾリル尿素誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8188289B2 (enExample) |
| EP (1) | EP2029539B1 (enExample) |
| JP (1) | JP5298005B2 (enExample) |
| KR (1) | KR20080109846A (enExample) |
| CN (1) | CN101405264B (enExample) |
| AR (1) | AR059826A1 (enExample) |
| AU (1) | AU2007225170B2 (enExample) |
| BR (1) | BRPI0708788A2 (enExample) |
| CA (1) | CA2646154A1 (enExample) |
| EA (1) | EA200801969A1 (enExample) |
| IL (1) | IL193539A0 (enExample) |
| MX (1) | MX2008011667A (enExample) |
| NZ (1) | NZ570657A (enExample) |
| TW (1) | TW200808723A (enExample) |
| WO (1) | WO2007106525A1 (enExample) |
| ZA (1) | ZA200807266B (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003078448A1 (en) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
| WO2004089296A2 (en) * | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
| WO2006045119A2 (en) | 2004-10-20 | 2006-04-27 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| WO2006084033A1 (en) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| WO2007022059A2 (en) * | 2005-08-12 | 2007-02-22 | The Regents Of The University Of California | Inhibition of phosphatase activity of soluble epoxide hydrolase amino terminus and uses thereof |
| EP2066642A1 (en) * | 2006-09-25 | 2009-06-10 | Arete Therapeutics, INC. | Soluble epoxide hydrolase inhibitors |
| CA2666482A1 (en) * | 2006-10-20 | 2008-05-02 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| EP2081898A2 (en) * | 2006-10-20 | 2009-07-29 | Arete Therapeutics, INC. | Adamantylurea compounds as soluble epoxide hydrolase inhibitors |
| JP2010509236A (ja) * | 2006-11-03 | 2010-03-25 | アレテ セラピューティクス， インコーポレイテッド | 慢性関節リウマチの処置のための可溶性エポキシドヒドロラーゼ阻害剤 |
| CA2675448A1 (en) * | 2007-01-29 | 2008-08-07 | Arete Therapeutics, Inc. | Processes for the preparation of piperidinyl-substituted urea compounds |
| BRPI0807829A2 (pt) * | 2007-01-29 | 2014-08-05 | Arete Therapeutics Inc | " inibidores de epóxido hidrolase solúvel para o tratamento de síndrome metabólica e desordens relacionadas ". |
| JP2010521456A (ja) * | 2007-03-13 | 2010-06-24 | アレテ セラピューティクス， インコーポレイテッド | 可溶性エポキシドヒドロラーゼ阻害剤 |
| JP5675343B2 (ja) * | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としての尿素誘導体 |
| WO2009020960A1 (en) * | 2007-08-06 | 2009-02-12 | The Regents Of The University Of California | Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase |
| WO2009035951A2 (en) * | 2007-09-11 | 2009-03-19 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| JP5411867B2 (ja) * | 2007-10-11 | 2014-02-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびそれらの使用 |
| EP2217068A4 (en) * | 2007-10-11 | 2011-09-14 | Glaxosmithkline Llc | NOVEL INHIBITORS OF SEH AND THEIR USE |
| MY157116A (en) | 2007-10-11 | 2016-05-13 | Glaxosmithkline Llc | Novel seh inhibitors and their use |
| WO2009062073A1 (en) | 2007-11-08 | 2009-05-14 | Regents Of The University Of California | Alleviating neuropathic pain with eets and seh inhibitors |
| WO2009073772A1 (en) * | 2007-12-06 | 2009-06-11 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| WO2009086426A2 (en) * | 2007-12-28 | 2009-07-09 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction |
| WO2009129501A1 (en) * | 2008-04-18 | 2009-10-22 | Arete Therapeutics, Inc. | Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders |
| AR071377A1 (es) * | 2008-04-18 | 2010-06-16 | Arete Therapeutics Inc | Inhibidores de epoxido hidrolasa soluble |
| CN102014897B (zh) | 2008-04-21 | 2015-08-05 | 西格纳姆生物科学公司 | 化合物、组合物和其制备方法 |
| WO2010025043A1 (en) * | 2008-08-29 | 2010-03-04 | Arete Therapeutics, Inc. | Use of soluble epoxide hydrolase inhibitors in the treatment of inflammatory vascular diseases |
| EP2334180A4 (en) * | 2008-09-15 | 2013-07-03 | Univ California | RESTRICTING DISEASES WITH A COMBINATION OF ACTIVE SUBSTANCES TO INCREASE THE CONCENTRATION OF EPOXYGENATED FATTY ACIDS AND ACTIVE SUBSTANCES TO INCREASE THE CAMP CONCENTRATION |
| WO2010096722A1 (en) | 2009-02-20 | 2010-08-26 | Takeda Pharmaceutical Company Limited | 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors |
| TW201041868A (en) * | 2009-03-20 | 2010-12-01 | Intervet Int Bv | Anthelmintic agents and their use |
| US20110065756A1 (en) * | 2009-09-17 | 2011-03-17 | De Taeye Bart M | Methods and compositions for treatment of obesity-related diseases |
| EP2528604B1 (en) * | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| WO2011143607A1 (en) * | 2010-05-14 | 2011-11-17 | The Regents Of The University Of California | Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors |
| EP2744807A4 (en) | 2011-08-15 | 2015-03-04 | Intermune Inc | COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS |
| JPWO2013115294A1 (ja) * | 2012-01-31 | 2015-05-11 | 東レ株式会社 | ジアザスピロウレア誘導体及びその医薬用途 |
| US20150065717A1 (en) * | 2012-03-29 | 2015-03-05 | Toray Industries, Inc. | Nipecotic acid derivative and use thereof for medical purposes |
| EP2945950B1 (en) | 2013-01-17 | 2017-03-01 | Sanofi | Isomannide derivatives as inhibitors of soluble epoxide hydrolase |
| WO2014193969A2 (en) * | 2013-05-28 | 2014-12-04 | The Regents Of The University Of California | Compounds for the treatment of hypertension and hypertensive end stage renal disease |
| EP2881390A1 (en) | 2013-12-04 | 2015-06-10 | Sanofi | Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase |
| BR112016021641A2 (pt) | 2014-03-27 | 2017-08-15 | Eicosis Llc | Potentes inibidores da epóxido hidrolase solúveis |
| PL3925607T5 (pl) | 2014-04-15 | 2026-06-01 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
| US10813894B2 (en) | 2015-02-20 | 2020-10-27 | The Regents Of The University Of California | Methods of inhibiting pain |
| CA2993882A1 (en) * | 2015-07-28 | 2017-02-02 | Universitat De Barcelona | Analogs of adamantylureas as soluble epoxide hydrolase inhibitors |
| KR101947976B1 (ko) | 2015-12-15 | 2019-02-13 | 아스트라제네카 아베 | 이소인돌 화합물 |
| WO2017127306A1 (en) | 2016-01-18 | 2017-07-27 | Arisan Therapeutics | Adamatane derivatives for the treatment of filovirus infection |
| EP3463470A1 (en) | 2016-05-25 | 2019-04-10 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Treatment and diagnosis of non-proliferative diabetic retinopathy |
| EP3638661A1 (en) | 2017-06-14 | 2020-04-22 | Astrazeneca AB | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
| US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
| EP3584236A1 (en) * | 2018-06-20 | 2019-12-25 | Universitat de Barcelona | Polycyclic compounds soluble epoxide hydrolase inhibitors |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| US20230192626A1 (en) * | 2020-05-26 | 2023-06-22 | Baylor College Of Medicine | Novel soluble epoxide hydrolase inhibitors and method of use thereof |
| WO2022076881A1 (en) * | 2020-10-09 | 2022-04-14 | The Regents Of The University Of California | Methods of treating alzheimer's disease using slow tight binding soluble epoxide hydrolase inhibitors |
| US11766419B2 (en) | 2021-01-08 | 2023-09-26 | Banasthali Vidyapith | Mebeverine as soluble epoxide hydrolase inhibitor |
| EP4063348A1 (en) | 2021-03-24 | 2022-09-28 | Universitat de Barcelona | Compounds as soluble epoxide hydrolase inhibitors |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| CN115819326B (zh) * | 2021-09-16 | 2025-04-08 | 武汉熙瑞医药科技有限公司 | 一种酰胺类化合物、其制备方法及其应用 |
| CN116924966B (zh) * | 2023-07-19 | 2026-06-19 | 沈阳药科大学 | 美金刚衍生物及其制备方法和在制备治疗可溶性环氧化物酶介导的疾病的药物中的应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE757606A (fr) | 1969-10-21 | 1971-04-01 | Western Electric Co | Systeme de traitement de donnees |
| US3703537A (en) | 1969-10-28 | 1972-11-21 | Cilag Chemie | Adamantyl urea derivatives |
| US3755415A (en) | 1969-10-28 | 1973-08-28 | Cilag Chem Ag | Adamantyl urea derivatives |
| DD123466A1 (enExample) | 1975-12-01 | 1976-12-20 | ||
| US4252954A (en) | 1979-10-25 | 1981-02-24 | Eli Lilly And Company | Salts of dihalo-3,4-dihydro-3-oxo-2-quinoxaline carboxylic acids and hindered amines |
| JPS58118567A (ja) * | 1982-01-07 | 1983-07-14 | Mitsui Toatsu Chem Inc | スルファモイル安息香酸誘導体 |
| US5273982A (en) | 1990-03-09 | 1993-12-28 | Hoffmann-La Roche Inc. | Acetic acid derivatives |
| JPH0413666A (ja) | 1990-05-08 | 1992-01-17 | Yamanouchi Pharmaceut Co Ltd | １―（アルコキシフェニル）―３―（４，５，６，７―テトラヒドロベンズイミダゾリル）ウレア |
| US5189036A (en) * | 1990-06-20 | 1993-02-23 | Schering Ag | Imidazolylbenzoyl substituted heterocycles |
| JPH05294935A (ja) | 1991-03-15 | 1993-11-09 | Green Cross Corp:The | アミノピリジン系化合物 |
| US5314902A (en) | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
| DE4319038A1 (de) * | 1993-06-08 | 1994-12-15 | Bayer Ag | Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung |
| US5445956A (en) | 1993-08-13 | 1995-08-29 | The Regents Of The University Of California | Recombinant soluble epoxide hydrolase |
| JPH07133224A (ja) | 1993-11-10 | 1995-05-23 | Kyowa Hakko Kogyo Co Ltd | 動脈硬化治療薬 |
| US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
| JP3583489B2 (ja) * | 1994-12-22 | 2004-11-04 | 日清紡績株式会社 | カルボジイミド誘導体 |
| US5877224A (en) | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
| AU1328197A (en) * | 1995-12-01 | 1997-06-19 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
| FR2750991A1 (fr) * | 1996-07-12 | 1998-01-16 | Pf Medicament | Nouveaux benzodioxannes et 1-(2h)-benzopyrannes, leur preparation et leur utilisation comme medicament |
| CA2261031A1 (en) | 1996-07-23 | 1998-01-29 | Charles A. Blum | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
| US6150415A (en) | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
| US6531506B1 (en) * | 1996-08-13 | 2003-03-11 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
| US6693130B2 (en) | 1999-02-18 | 2004-02-17 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
| DE69819903T2 (de) | 1997-08-09 | 2004-11-11 | Smithkline Beecham P.L.C., Brentford | Bicyclische verbindungen als liganden der 5-ht1 rezeptoren |
| AR016817A1 (es) * | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
| US6221425B1 (en) | 1998-01-30 | 2001-04-24 | Advanced Cardiovascular Systems, Inc. | Lubricious hydrophilic coating for an intracorporeal medical device |
| US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
| WO2000010622A1 (en) | 1998-08-20 | 2000-03-02 | Cook Incorporated | Coated implantable medical device |
| US6335029B1 (en) | 1998-08-28 | 2002-01-01 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
| AUPP818099A0 (en) | 1999-01-14 | 1999-02-11 | Fujisawa Pharmaceutical Co., Ltd. | New n-containing heterocyclic compounds |
| US6693202B1 (en) * | 1999-02-16 | 2004-02-17 | Theravance, Inc. | Muscarinic receptor antagonists |
| EP1031564A1 (en) * | 1999-02-26 | 2000-08-30 | Klinge Pharma GmbH | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy |
| US6351506B1 (en) | 1999-04-19 | 2002-02-26 | National Semiconductor Corporation | Switched capacitor filter circuit having reduced offsets and providing offset compensation when used in a closed feedback loop |
| US6156373A (en) | 1999-05-03 | 2000-12-05 | Scimed Life Systems, Inc. | Medical device coating methods and devices |
| US6344358B1 (en) | 1999-05-28 | 2002-02-05 | Fujisawa Pharmaceutical Co., Ltd. | Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property |
| CO5190710A1 (es) | 1999-06-15 | 2002-08-29 | Smithkline Beecham Corp | Antagonistas de un receptor de il-8 un receptor de il-8 |
| US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| JP4548884B2 (ja) * | 1999-12-03 | 2010-09-22 | 興和創薬株式会社 | ４，５，６，７−テトラヒドロチエノ〔２，３−ｃ〕ピリジン誘導体 |
| ATE299494T1 (de) | 1999-12-07 | 2005-07-15 | Theravance Inc | Carbamat-derivate als muscarin-rezeptor antonisten |
| UA73543C2 (uk) | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
| US6290722B1 (en) | 2000-03-13 | 2001-09-18 | Endovascular Technologies, Inc. | Tacky attachment method of covered materials on stents |
| US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| US6645990B2 (en) * | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| DE10051321A1 (de) * | 2000-10-17 | 2002-04-25 | Boehringer Ingelheim Pharma | Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| AU2002355286B2 (en) * | 2001-07-26 | 2005-10-13 | Schering Corporation | Substituted urea neuropeptide Y Y5 receptor antagonists |
| US20040242637A1 (en) * | 2001-08-17 | 2004-12-02 | Hartman George D | Tyrosine kinase inhibitors |
| WO2003062234A1 (en) * | 2002-01-23 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Quinoxaline compounds |
| US20030139469A1 (en) | 2002-01-23 | 2003-07-24 | The Regents Of The University Of California | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation |
| GB0203994D0 (en) | 2002-02-20 | 2002-04-03 | Celltech R&D Ltd | Chemical compounds |
| MXPA04008517A (es) * | 2002-03-04 | 2005-08-19 | Pharmacia & Upjohn Co Llc | Compuestos terapeuticos. |
| TW200400035A (en) | 2002-03-28 | 2004-01-01 | Glaxo Group Ltd | Novel compounds |
| ES2197003B1 (es) * | 2002-04-08 | 2005-03-16 | J. URIACH & CIA S.A. | Nuevos compuestos antagonistas de integrinas alfa. |
| AU2003241453A1 (en) | 2002-05-17 | 2003-12-02 | Janssen Pharmaceutica N.V. | Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
| GB0211759D0 (en) | 2002-05-22 | 2002-07-03 | Glaxo Group Ltd | Novel compounds |
| US7183411B2 (en) * | 2002-07-12 | 2007-02-27 | Janssen Pharmaceutica N.V. | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor |
| GB0218326D0 (en) * | 2002-08-07 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| AU2003270199A1 (en) * | 2002-09-13 | 2004-04-30 | Glaxo Group Limited | Urea compounds active as vanilloid receptor antagonists for the treatment of pain |
| KR20050043967A (ko) | 2002-09-17 | 2005-05-11 | 액테리온 파마슈티칼 리미티드 | 1-피리딘-4-일-요소 유도체 |
| US7186725B2 (en) * | 2003-01-03 | 2007-03-06 | Genzyme Corporation | Anti-inflammatory compositions and methods |
| US7399866B2 (en) | 2003-01-14 | 2008-07-15 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2004089296A2 (en) | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| GB0308801D0 (en) * | 2003-04-16 | 2003-05-21 | Celltech R&D Ltd | Chemical compounds |
| PT1658269E (pt) * | 2003-06-12 | 2009-01-09 | Abbott Lab | Compostos condensados que inibem o receptor vanilóide de subtipo 1 (vr1) |
| CA2526204A1 (en) * | 2003-06-12 | 2004-12-23 | Novo Nordisk A/S | Pyridinyl carbamates as hormone-sensitive lipase inhibitors |
| JP2007501805A (ja) | 2003-08-08 | 2007-02-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピリジルピペラジニルウレア |
| JP4851328B2 (ja) * | 2003-09-26 | 2012-01-11 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピリジン誘導体 |
| WO2005037199A2 (en) | 2003-10-10 | 2005-04-28 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| CN1918172B (zh) * | 2003-12-23 | 2011-09-14 | 活跃生物工艺学公司 | 利福霉素类似物及其用途 |
| JP2007529496A (ja) | 2004-03-19 | 2007-10-25 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 抗菌剤としてのイミダゾピリジン及びイミダゾピリミジン誘導体 |
| AU2005245389A1 (en) | 2004-05-12 | 2005-12-01 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| SI1761520T1 (sl) * | 2004-06-23 | 2008-10-31 | Lilly Co Eli | Inhibitorji kinaze |
| AU2005270102A1 (en) * | 2004-07-02 | 2006-02-09 | Icos Corporation | Compounds useful for inhibiting Chk1 |
| FR2872813B1 (fr) * | 2004-07-09 | 2007-01-19 | Sanofi Synthelabo | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
| SE0401971D0 (sv) * | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| WO2006045119A2 (en) | 2004-10-20 | 2006-04-27 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
-
2007
- 2007-03-12 AR ARP070101011A patent/AR059826A1/es unknown
- 2007-03-12 TW TW096108378A patent/TW200808723A/zh unknown
- 2007-03-13 WO PCT/US2007/006412 patent/WO2007106525A1/en not_active Ceased
- 2007-03-13 MX MX2008011667A patent/MX2008011667A/es not_active Application Discontinuation
- 2007-03-13 US US11/685,674 patent/US8188289B2/en active Active
- 2007-03-13 EA EA200801969A patent/EA200801969A1/ru unknown
- 2007-03-13 JP JP2009500457A patent/JP5298005B2/ja not_active Expired - Fee Related
- 2007-03-13 NZ NZ570657A patent/NZ570657A/en not_active IP Right Cessation
- 2007-03-13 EP EP07753064.0A patent/EP2029539B1/en active Active
- 2007-03-13 AU AU2007225170A patent/AU2007225170B2/en not_active Ceased
- 2007-03-13 KR KR1020087025016A patent/KR20080109846A/ko not_active Withdrawn
- 2007-03-13 CA CA002646154A patent/CA2646154A1/en not_active Abandoned
- 2007-03-13 BR BRPI0708788-8A patent/BRPI0708788A2/pt not_active IP Right Cessation
- 2007-03-13 CN CN2007800092891A patent/CN101405264B/zh not_active Expired - Fee Related
- 2007-05-13 ZA ZA200807266A patent/ZA200807266B/xx unknown
-
2008
- 2008-08-19 IL IL193539A patent/IL193539A0/en unknown
-
2012
- 2012-04-25 US US13/455,861 patent/US8501783B2/en active Active
-
2013
- 2013-06-14 US US13/918,837 patent/US9029550B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8697727B2 (en) | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | |
| JP5298005B2 (ja) | 高血圧、炎症および他の疾患の治療のための可溶性エポキシドヒドロラーゼの阻害剤としてのピペリジニル、インドリル、ピリニジル、モルホリニルおよびベンズイミダゾリル尿素誘導体 | |
| EP1396487B1 (en) | Phenylpyridine carbonyl piperazine derivative | |
| CA2442227C (en) | Ccr5 antagonists useful for treating aids | |
| RU2009126624A (ru) | Производные 2-(пиперидин-4-ил)-4-фенокси-или фенилаинопиримидина в качестве ненуклеозидных ингибитров обратной транскриптазы | |
| JP2005513123A5 (enExample) | ||
| HU182965B (en) | Process for preparing new n-heterocyclyl-piperidine-4-amine derivatives and acid addition salts thereof | |
| TWI364420B (en) | Novel piperazine amide derivatives | |
| HUP0302153A2 (hu) | Kemokin receptor aktívitás modulátoraiként hatásos piperidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| RU2010150911A (ru) | Амидное соединение | |
| SK5432002A3 (en) | Substituted indoles for modulating nfkb activity | |
| JP2008543919A5 (enExample) | ||
| RU2008145704A (ru) | Пуриновые производные в качестве агонистов a2a-рецептора | |
| RU2011138970A (ru) | Активаторы растворимой гуанилатциклазы | |
| JP2009545612A (ja) | 可溶性エポキシド加水分解酵素阻害剤 | |
| CA2667481A1 (en) | New phenylsulfamoyl benzamide derivatives as bradykinin antagonists | |
| RU2008140910A (ru) | Новые пиперидины в качестве модуляторов хемокинов (ccr) | |
| SK272003A3 (en) | Piperidine compounds for use as CCR-3 inhibitors | |
| MX2013003479A (es) | Derivados de benzazol como ligandos del receptor h4 de histamina. | |
| JP4064059B2 (ja) | インテグリンαＶβ３拮抗剤としてのアミノピペリジン誘導体 | |
| ES2414159T3 (es) | Antagonistas de acrilamida piperidilo de CCR2 | |
| JP2005525309A (ja) | 医薬品としての使用のためのＭＴＰインヒビター又はａｐｏＢ分泌インヒビターとフィブレートの組み合わせ | |
| CN1215392A (zh) | 组胺h3受体配体 | |
| JP2005504093A5 (enExample) | ||
| RU2013124814A (ru) | Гетероциклические производные диазенийдиолата |